**Multiple IPOs are scheduled to price and begin trading in the final days of September 2026, including Accelevation Holdings Corp. targeting $660 million and several smaller direct listings or traditional offerings set for September 30.** With 249 U.S. IPOs already completed year-to-date raising substantial proceeds, the active pipeline of S-1 filings and near-term pricings—spanning industrials, technology, and healthcare—makes additional listings before year-end highly likely. Market sentiment reflects selectivity amid elevated Treasury yields and AI-related volatility, yet institutional demand has supported recent deals like ADARx Pharmaceuticals. Key near-term catalysts include these late-September debuts and any follow-on activity through December, with broader conditions hinging on equity market stability and rate expectations. Trader consensus prices near-certain resolution well before 2027 given the compressed timeline.